期刊文献+

胸腺瘤患者血清sFas水平与重症肌无力相关性研究 被引量:2

The Study on Serum sFas Levels and Myasthenia Gravis in Patients with Thymoma
下载PDF
导出
摘要 目的检测胸腺瘤患者血清可溶性Fas(sFas)水平,探讨重症肌无力(Myasthenia Gravis,MG)的发病机制。方法将131例胸腺瘤患者根据是否合并MG分成AB两组,A组70例,B组61例,应用ELISA法检测血清sFas水平。对两组结果进行统计分析。结果两组间比较,A组患者血清sFas水平明显高于B组,差异极显著(P〈0.001);两组间同分型同分期胸腺瘤间sFas差异极显著(P〈O.001);同组间无论胸腺瘤分型或分期是否相同sFas水平无统计学差异(P〉O.05):单纯眼肌型MG患者血清sFas明显低于其他临床分型MG(P〈O.001)。结论胸腺瘤的生物学特性与MG的发生无直接相关性,Fas基因和蛋白结构的变异可能是MG发生的直接原因,通过进一步研究,血清sFas水平可能作为评价病情和疗效的客观指标。 Objective To detect the expression of serum soluble Fas(sFas) in patients with thymoma,and to investigate the pathogenesis of myasthenia gravis(MG).Methods According to being associated with MG or not,131 patients with thymoma were divided into two groups:70 cases in Group A,61 cases in Group B.The expression of serum sFas was detected by ELISA,and the results of both groups were subjected to statistical analysis using t test.Results The expression level of sFas in Group A was significantly higher than that in Group B(P〈0.001),and there was a statistical difference between patients with the same type and stage in both Group A and Group B(P〈0.001).However,the results showed no statistical difference in the same group whether the patients were with identical types,stage or not.Furthermore,an apparent expression decrease of sFas was manifested in simple ocular MG patients compared to other clinical types(P〈0.001).Conclusions The characteristics of thymoma were not correlated with MG.The mutation of Fas gene and protein may result in the development of MG,and to further study, serum sFas may be provided as an indicator of disease assessment and curative effect.
出处 《中国血液流变学杂志》 CAS 2012年第2期274-276,共3页 Chinese Journal of Hemorheology
基金 辽宁省自然科学基金资助项目(20042088)
关键词 胸腺瘤 重症肌无力 可溶性FAS thymoma myasthenia gravis soluble Fas
  • 相关文献

参考文献8

  • 1Wu JM,Wu B,Miagkov A,et al.Specific immunotherapy of experimental myasthenia gravis in vitro:the "guided missile" strategy[J].Cell Immunol,2001,208(2):137~147.
  • 2李作孝,惠红霞,赖成虹,赵振宇.重症肌无力患者血清可溶性Fas水平变化及其临床意义[J].临床神经病学杂志,2006,19(6):411-413. 被引量:7
  • 3Ben-David H,Sela M,Mozes E.Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis[J].Proc Natl Acad Sci USA,2005,102(6):2028~2033.
  • 4Aruna BV,Ben-David H,Sela M,et al.A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis[J].Immunology,2006,118(3):413~424.
  • 5谭清华,赵忠新,张玲珍.Fas和FasL在多发性硬化患者表达的意义[J].中华神经科杂志,2003,36(1):14-16. 被引量:4
  • 6戴勇,王沙燕,齐晖,黄瑞芳,李体远,张阮章,罗秀霞.狼疮肾炎患者血清sFas和sFasL的变化[J].风湿病学杂志,2000,4(2):89-91. 被引量:7
  • 7杜英,阮丽荣,张清勇,何炜,李倩如.重症肌无力患者胸腺细胞基因突变的初步探讨[J].免疫学杂志,2003,19(5):372-374. 被引量:2
  • 8Drachman DB,Wu JM,Miagkov A,et al.Specific immunotherapy of experimental myasthenia by genetically engineered APCs:the "guided missile" strategy[J].Ann N Y Acad Sci,2003,998:520~532.

二级参考文献18

  • 1赖成虹,李作孝.Fas和Bcl-2与重症肌无力[J].医学综述,2005,11(2):153-154. 被引量:6
  • 2[1]Kawaguchi N,Hattori T.Myasthenia gravis[J].Nippon Rinsho,2005,63(Suppl 5):S416.
  • 3[3]Oosterhuis HJ,Limburg PC,Hummel-Tappel E,et al.Anti-acety-lcholine receptor antibodies in MG[J].J Neuro Sci,1983,58:371.
  • 4[5]Balandina A,Lecart S,Dartevelle P,et al.Functional defect of regulatory CD+4CD+25 T cells in the thymus of patients with autoimmune myasthenia gravis[J].Blood J,2005,105:735.
  • 5[6]Cippitelli M,Fionda C,Di Bona D,et al.Negative regulation of CD95 ligand gene expression by vitamin D3 in T lym pho-cytes[J].J Immuo1,2002,168:1154.
  • 6[7]Ben-David H,Sela M,Mozes E.Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD+4CD+25-regulated events leading to apoptosis[J].Proc Natl Acad Sci USA,2005,102:2028.
  • 7[8]Deng C,Goluszko E,Christadoss P.Fas/FasL ligand pathway,apoptosis,and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance[J].J Immunol,2001,166:3458.
  • 8[9]Leussink VI,Jung S,Merschdorf U,et al.High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes[J].Arch Neurol,2001,58:91.
  • 9Ju SF, Panka DJ, Cui H, et al. Fas(CD95)/FasL interaction required for programmed cell death after T-cell activa6on[J].Nature, 1995,373(6 513) :444 - 448.
  • 10Ogasawara J, Suda T, Nagata S. Selective apoptosis of CD4^+ CD8^+ thymocytes by the anti-Fas antibody[J]. J Exp Med,1995,181(2) :485 - 496.

共引文献15

同被引文献21

  • 1张其刚,李进东,尚文军,谢成耀,刘楠.胸腺瘤旁胸腺组织Fas及其配体表达在重症肌无力发病中的意义[J].中华神经科杂志,2005,38(1):46-48. 被引量:3
  • 2魏雪飞,许贤豪,张华,胡文立.重症肌无力患者胸腺细胞经AChR刺激后T淋巴细胞亚群Bcl-2的表达[J].中国神经免疫学和神经病学杂志,2006,13(1):1-4. 被引量:3
  • 3Weker H. The thymus in myasthenia gravis[J]. Ann NY Acad Sci,1993,681(3) :47-53.
  • 4Baggi F, Annoni A, Ubiali F. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induce ex- perimental myasthenia gravis in ret[J]. Immunol, 2004, 172: 2897-2703.
  • 5Suzuki Y, Onodera H, Tago H, et al. Altered populations of natural killer cell and natural kill T cell subclasses in myasthe nia gravis[J]. Neuroimmunol, 2005, 167(10) : 186-189.
  • 6Straussg G, Knape I, Melzner I, et al. Constitutive caspase activation and impaired death-inducing signaling complex for mation in CD95 resistant long term activated antigen specific Tcell[J]. Immunol, 2003, 171(3): 1172-1182.
  • 7Ben-David H, Sela M, Mozes E. Down-regulation of myas- thenogenic T cell responses by a dual altered peptide ligand via CD4+ CD25+-regulated events leading to apoptosis[J]. Proc Natl Acad Sci USA, 2005, 102: 2028-2033.
  • 8Walezak H, Miller RE, Arial K, et al. Tumoricidal activity of tumornecrosis factor-related apoptosis inducing ligand in vi- vo[J]. Nat Med, 1999, 5(2): 157-163.
  • 9Aruna BV, Ben-David H, Sela M, et al. Adual altered pep- tide ligand down-regulates of myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-Fasl mediated apoptosis[J]. Immunolo gy, 2006,118(3) : 413-424.
  • 10Krueger A, Fas SC, Giaisi M, et al. HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FL ICE-inhibitory protein (c-FLIP) [J]. Blood, 2006, 107 (10):3933-3939.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部